Related Experiment Video
Updated: Jan 26, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Immunotherapy in Hodgkin Lymphoma: The Road Ahead
1Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA.
Abstract:
An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgkin lymphoma (cHL) but these cells do result in an effective antitumor response. Immune checkpoint therapy, which activates 'exhausted' T cells, has been found to be highly effective in cHL, but responding patients commonly relapse. Combination approaches are currently being investigated but the assessment of benefit when adding immunotherapy is challenging. The pitfalls in designing combination studies derive from response endpoints that are difficult to measure, a lack of biomarkers that predict response, and a limited understanding of tumor biology. While progress in treating patients with cHL has been exceptional so far, further progress may require a review of clinical trial endpoints and a greater understanding of cHL biology.
Related Concept Videos
Tumor Immunotherapy
Design Example: Alignment of a Road Line Using GIS
Habitat Fragmentation
Archival Research
Social Traps

